Bonviva: Uses, Dosage & Side Effects
A once-monthly bisphosphonate tablet that treats postmenopausal osteoporosis by inhibiting bone resorption and reducing vertebral fracture risk
Bonviva (ibandronic acid) is a nitrogen-containing bisphosphonate medication prescribed for the treatment of postmenopausal osteoporosis. Taken as a single 150 mg film-coated tablet once a month, Bonviva works by inhibiting osteoclast-mediated bone resorption, leading to increased bone mineral density and reduced fracture risk. The MOBILE study demonstrated that the once-monthly 150 mg dose produced statistically superior gains in lumbar spine bone mineral density compared to the 2.5 mg daily dose. Bonviva offers the convenience of once-monthly dosing, which has been shown to improve patient adherence compared to weekly bisphosphonate regimens. Like all oral bisphosphonates, it requires careful administration — taken on an empty stomach with plain water while remaining upright for at least 60 minutes — to ensure proper absorption and prevent esophageal irritation.
Quick Facts: Bonviva
Key Takeaways
- Bonviva is a once-monthly bisphosphonate tablet (150 mg) for treating postmenopausal osteoporosis, offering improved adherence over weekly dosing regimens.
- The MOBILE study showed the 150 mg monthly dose produced significantly greater increases in lumbar spine bone mineral density than the 2.5 mg daily dose after two years.
- Must be taken on an empty stomach with a full glass of plain tap water, followed by remaining upright for at least 60 minutes before eating, drinking, or taking other medications.
- Rare but serious risks include osteonecrosis of the jaw (ONJ), atypical femur fractures, and esophageal ulceration — dental evaluation is recommended before starting treatment.
- Treatment duration is typically reassessed after 3–5 years, with a “drug holiday” considered depending on individual fracture risk and bone density status.
What Is Bonviva and What Is It Used For?
Bonviva contains the active substance ibandronic acid, a nitrogen-containing bisphosphonate that belongs to a group of medicines used to treat bone disorders. Bisphosphonates work by binding to the mineral surface of bone and specifically targeting osteoclasts — the cells responsible for breaking down bone tissue. By inhibiting the enzyme farnesyl pyrophosphate synthase within the mevalonate pathway, ibandronic acid triggers osteoclast apoptosis (programmed cell death) and dramatically reduces the rate of bone resorption. This allows the bone-building cells (osteoblasts) to work more effectively, resulting in progressive gains in bone mineral density over time.
The primary indication for Bonviva is the treatment of postmenopausal osteoporosis in women at increased risk of fracture. Osteoporosis is a systemic skeletal disease characterized by reduced bone mass and deterioration of bone microarchitecture, leading to increased bone fragility and susceptibility to fractures. After menopause, the decline in estrogen levels accelerates bone turnover, with resorption outpacing formation. This imbalance can result in a loss of up to 3–5% of bone mass per year in the first five to seven years after menopause, significantly increasing the risk of vertebral, hip, and wrist fractures.
The efficacy of Bonviva was established in several pivotal clinical trials. The BONE study (oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe) was a landmark randomized, double-blind, placebo-controlled trial involving 2,946 postmenopausal women with osteoporosis. Over three years, daily oral ibandronate (2.5 mg) reduced the incidence of new morphometric vertebral fractures by 62% compared to placebo (Chesnut et al., Journal of Bone and Mineral Research, 2004). The study demonstrated significant reductions in vertebral fracture risk and improvements in bone mineral density at the lumbar spine and hip.
The MOBILE study (Monthly Oral iBandronate In LadiEs) was a randomized, double-blind trial that compared the once-monthly 150 mg dose with the daily 2.5 mg dose in 1,609 postmenopausal women with osteoporosis. After two years, the monthly 150 mg dose produced statistically superior increases in lumbar spine bone mineral density (+6.6%) compared to the daily dose (+5.0%), confirming that the monthly regimen is at least as effective — and possibly more effective — than daily dosing (Miller et al., Journal of Bone and Mineral Research, 2005). This study provided the clinical evidence for the once-monthly 150 mg tablet that is now the standard oral formulation of Bonviva.
One of the key advantages of Bonviva is its once-monthly dosing schedule. Research has consistently shown that patients taking osteoporosis medications adhere better to monthly regimens than to weekly ones. The BALTO (Bonviva ALendronate Trial in Osteoporosis) study found that two out of three women with osteoporosis preferred once-monthly ibandronate over once-weekly alendronate, with convenience being the primary reason cited (Emkey et al., Current Medical Research and Opinion, 2005). Better adherence translates to better treatment outcomes, as poor adherence to bisphosphonate therapy is associated with suboptimal fracture risk reduction.
In addition to pharmacological treatment, healthcare providers typically recommend lifestyle modifications to support bone health. These include regular weight-bearing and muscle-strengthening exercise, adequate calcium intake (1,000–1,200 mg daily), sufficient vitamin D (800–1,000 IU daily), smoking cessation, limiting alcohol consumption, and fall prevention strategies. Bonviva works best as part of a comprehensive osteoporosis management plan that addresses both medical and lifestyle factors.
What Should You Know Before Taking Bonviva?
Bonviva is not suitable for everyone. Before starting treatment, your healthcare provider will evaluate your medical history, current medications, and overall health to determine whether this medication is appropriate for you. A thorough discussion about existing health conditions is important because several factors can influence whether Bonviva is safe and effective for your particular situation. Your doctor may also order blood tests to check your calcium levels, kidney function, and vitamin D status before prescribing Bonviva.
Bonviva is specifically indicated for postmenopausal women with osteoporosis. It is not approved for use in premenopausal women, men, or children. The decision to prescribe Bonviva is typically based on bone mineral density measurements (DXA scan), clinical risk factors for fractures, or a history of fragility fractures.
Contraindications
You should not take Bonviva if any of the following apply:
- You are allergic to ibandronic acid or any of the other ingredients in the tablet (lactose monohydrate, povidone, microcrystalline cellulose, crospovidone, stearic acid, colloidal anhydrous silica)
- You have abnormalities of the esophagus such as stricture (narrowing) or achalasia (impaired motility that prevents food from passing to the stomach)
- You are unable to stand or sit upright for at least 60 minutes after taking the tablet
- You have or have recently had low blood calcium levels (hypocalcemia) — this must be corrected before starting Bonviva
- You have severe kidney impairment (creatinine clearance below 30 ml/min)
Warnings and Precautions
Talk to your doctor or pharmacist before taking Bonviva if any of the following conditions apply to you:
- Kidney problems — Bonviva is not recommended for patients with severe renal impairment (creatinine clearance below 30 ml/min). Dosage adjustment is not required for mild to moderate kidney disease, but your doctor may choose to monitor your kidney function more closely
- Swallowing or digestive problems — including Barrett’s esophagus, difficulty swallowing (dysphagia), active upper gastrointestinal disease, gastritis, duodenitis, or ulcers
- Low calcium or vitamin D levels — hypocalcemia and other disturbances of mineral metabolism must be effectively treated before starting Bonviva. Adequate intake of calcium and vitamin D is important in all patients
- Malabsorption syndromes — conditions affecting mineral absorption in the gastrointestinal tract may impair Bonviva absorption
- History of gastrointestinal surgery — particularly gastric bypass or procedures that may affect the esophagus or stomach
A dental examination with appropriate preventive dentistry should be considered before starting treatment with Bonviva, particularly in patients with concomitant risk factors. These risk factors include cancer, chemotherapy, radiotherapy, corticosteroid therapy, poor oral hygiene, periodontal disease, tooth extractions, poorly fitting dentures, and smoking. Osteonecrosis of the jaw (ONJ) — a rare condition involving exposed or necrotic bone in the jaw — has been reported in patients receiving bisphosphonates. The risk appears to be higher with intravenous bisphosphonates and in patients with cancer, but cases have also occurred with oral bisphosphonates used for osteoporosis. During treatment, maintain good oral hygiene and attend regular dental check-ups. Inform your dentist that you are taking Bonviva before any invasive dental procedures, especially tooth extractions or implant placement.
Irritation, inflammation, or ulceration of the esophagus can occur with Bonviva use, particularly if patients do not drink a full glass of water with the tablet, lie down within 60 minutes of taking it, or continue taking Bonviva after developing symptoms of esophageal irritation. Stop taking Bonviva and contact your doctor immediately if you experience difficulty swallowing, pain on swallowing, retrosternal pain (pain behind the breastbone), or new or worsening heartburn.
Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These unusual fractures can occur with minimal or no trauma in the thigh bone. If you develop new or unusual pain in the hip, groin, or thigh during Bonviva treatment, report it to your doctor promptly, as this may be an early indication of an incomplete fracture. Both legs should be examined, as bilateral involvement has been observed.
Pregnancy and Breastfeeding
Bonviva is indicated only for use in postmenopausal women and should not be taken during pregnancy or breastfeeding. There is limited clinical experience with ibandronic acid in pregnant women. In animal studies, reproductive toxicity was observed at high doses. Because bisphosphonates are incorporated into the bone matrix and are released gradually over years, the degree of fetal exposure is related to the duration of bisphosphonate use and the time between discontinuation and conception. If you suspect you may be pregnant or are planning a pregnancy, consult your healthcare provider immediately.
It is not known whether ibandronic acid is excreted in human breast milk. Studies in lactating rats have shown low levels of ibandronic acid in milk. Bonviva should not be used during breastfeeding.
Driving and Using Machines
Based on the pharmacodynamic and pharmacokinetic profile and reported adverse reactions, Bonviva is expected to have no or negligible influence on the ability to drive and use machines. However, individual responses may vary, and some patients have reported dizziness or visual disturbances. If you experience such effects, do not drive or operate machinery until the symptoms resolve.
How Does Bonviva Interact with Other Drugs?
Drug interactions can significantly affect how well Bonviva works or increase the risk of adverse effects. The oral bioavailability of ibandronic acid is already low (approximately 0.6% under fasting conditions), and any food, beverages (other than plain tap water), or medications taken concurrently can further reduce absorption by up to 90%. This means that the timing of administration relative to other substances is critically important for treatment efficacy.
It is essential to inform your doctor or pharmacist about all medications you are taking, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins. Below is a summary of the most important drug interactions:
Major Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Calcium supplements | Significantly reduces ibandronic acid absorption by forming insoluble calcium-bisphosphonate complexes in the gut | Take calcium at least 60 minutes after Bonviva (preferably with lunch or dinner) |
| Antacids (aluminum, magnesium, calcium-containing) | Polyvalent cations substantially reduce ibandronic acid absorption | Wait at least 60 minutes after Bonviva before taking any antacid |
| Iron supplements | May reduce ibandronic acid absorption through chelation | Take iron supplements at a different time of day, at least 60 minutes after Bonviva |
| NSAIDs (ibuprofen, naproxen, aspirin) | Increases risk of gastrointestinal irritation, ulceration, and bleeding when combined with bisphosphonates | Use with caution; discuss regular NSAID use with your doctor |
| Aminoglycosides (gentamicin, tobramycin) | Both bisphosphonates and aminoglycosides can lower serum calcium levels; combined use may increase risk of hypocalcemia | Monitor calcium levels closely if concurrent use is necessary |
Minor Interactions
Proton pump inhibitors (PPIs) such as omeprazole and pantoprazole may theoretically affect bisphosphonate absorption through altered gastric pH. However, a pharmacokinetic study showed that pretreatment with the H2-receptor antagonist ranitidine increased the bioavailability of ibandronic acid by approximately 20%, likely by reducing gastric acid degradation of the bisphosphonate. Despite this, the clinical significance of this interaction is considered minor and no dose adjustment is required when using Bonviva with acid-suppressing medications.
Hormone replacement therapy (HRT) can be used alongside Bonviva. In the BONE study, approximately 50% of patients received concomitant HRT without any negative impact on efficacy or safety. However, the combination is not routinely recommended in current guidelines, as the added benefit is generally modest.
Vitamin D supplements should be taken concurrently with Bonviva therapy, but not at the same time as the tablet. Vitamin D supplements can be taken with any meal during the day, as they do not interfere with ibandronic acid absorption when separated by at least 60 minutes.
Unlike some other oral bisphosphonates that require a 30-minute wait, Bonviva requires a minimum of 60 minutes before eating, drinking anything other than plain water, or taking other medications. This extended fasting period is specific to ibandronic acid and is necessary because of its extremely low oral bioavailability. Even small amounts of food or drink can reduce absorption to negligible levels, rendering the medication ineffective.
What Is the Correct Dosage of Bonviva?
Always take Bonviva exactly as prescribed by your doctor. The recommended dose is one 150 mg film-coated tablet taken orally once a month. The same date each month should be chosen for dosing (for example, the 1st of each month). Consistency in timing helps establish a routine and reduces the risk of missed doses.
Adults
Postmenopausal Osteoporosis (Treatment)
Dose: 150 mg once monthly — take one film-coated tablet on the same date each month.
The once-monthly 150 mg dose has been shown to be non-inferior to and, for lumbar spine bone mineral density, statistically superior to the daily 2.5 mg dose in the MOBILE study. The monthly regimen provides the same cumulative drug exposure over 30 days as the daily dose, but with significantly better patient adherence and convenience.
Renal Impairment
Mild to moderate (creatinine clearance ≥30 ml/min): No dosage adjustment is required.
Severe (creatinine clearance <30 ml/min): Bonviva is not recommended due to limited clinical experience in this population.
Hepatic Impairment
No dosage adjustment is required. Ibandronic acid is not metabolized by the liver — it is cleared from the circulation by bone uptake and renal excretion.
How to Take Bonviva Correctly
The way you take Bonviva is critically important for both its effectiveness and your safety. Ibandronic acid has extremely low oral bioavailability (approximately 0.6%), and any deviation from the correct administration procedure can reduce absorption to virtually zero. Follow these instructions carefully:
- Choose your date: Select a date each month that is easy to remember. Take your tablet on the same date every month.
- Take it first thing in the morning: After waking up and before eating, drinking, or taking any other medication, swallow the tablet whole with a full glass of plain tap water (at least 200 ml / 7 fl oz).
- Do not use mineral water (still or sparkling), coffee, tea, juice, milk, or any other beverage — these can dramatically reduce absorption.
- Do not chew, crush, suck, or dissolve the tablet — swallow it whole to avoid mouth or throat ulcers.
- Stay upright for 60 minutes: After swallowing the tablet, remain sitting or standing for at least one full hour. Do not lie down during this time. This is longer than for some other bisphosphonates and is essential to prevent esophageal irritation.
- Wait before eating or taking other medicines: Do not eat, drink (except plain tap water), or take any other medication (including antacids, calcium, and vitamins) for at least 60 minutes after taking Bonviva.
- Do not take at bedtime or before getting up for the day.
Children
Bonviva should not be given to children and adolescents below 18 years of age. The safety and efficacy of ibandronic acid in pediatric populations have not been established. Bonviva is indicated solely for the treatment of postmenopausal osteoporosis.
Elderly
No dosage adjustment is required for elderly patients. In clinical trials, no overall differences in efficacy or safety were observed between patients aged 65 years and older compared to younger patients. Bonviva can be used at the standard dose of 150 mg once monthly in elderly postmenopausal women without modification.
Missed Dose
If you forget to take your Bonviva tablet on the scheduled date, the action to take depends on how far away the next scheduled dose is:
- If your next scheduled dose is more than 7 days away: Take the missed tablet the next morning after you remember. Then return to your original monthly schedule.
- If your next scheduled dose is within 7 days: Wait and take the next tablet on the originally scheduled date. Do not take a double dose to make up for the forgotten one.
After this, always return to your original chosen date. Never take two 150 mg tablets within the same week.
Overdose
If you accidentally take more than one tablet, drink a full glass of milk and contact a doctor or poison control center immediately. Do not induce vomiting and do not lie down — this could cause serious esophageal irritation. Overdose may cause upper gastrointestinal adverse events (stomach upset, heartburn, esophagitis, gastritis, or ulcer) and may lead to low blood calcium (hypocalcemia) and low blood phosphate (hypophosphatemia). Milk or antacids should be administered to bind ibandronic acid in the gastrointestinal tract.
What Are the Side Effects of Bonviva?
Like all medicines, Bonviva can cause side effects, although not everybody gets them. The majority of side effects are mild to moderate in severity and tend to diminish with continued use. Clinical trials with the 150 mg once-monthly dose showed a side effect profile similar to the daily 2.5 mg regimen, though flu-like symptoms (also called acute-phase reactions) were observed more frequently with the higher monthly dose, particularly after the first dose.
In the MOBILE study, the most frequently reported adverse events with the 150 mg monthly dose were dyspepsia (stomach discomfort), nausea, and musculoskeletal pain. The overall rate of serious adverse events was comparable between the monthly and daily dose groups. Gastrointestinal adverse events can be significantly reduced by following the correct administration instructions, particularly the requirement to remain upright for 60 minutes after taking the tablet.
- Difficulty swallowing or pain when swallowing
- Chest pain or new or worsening heartburn
- Severe allergic reactions (swelling of the face, lips, tongue, or throat; difficulty breathing; hives)
- Jaw pain, swelling, numbness, loosening of teeth, or poor healing after dental procedures
- New or unusual pain in the hip, groin, or thigh (may indicate an atypical femur fracture)
- Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
- Eye symptoms: pain, redness, blurred vision (may indicate uveitis, scleritis, or episcleritis)
Side Effect Frequency
Common
- Headache
- Flu-like illness (fever, chills, bone pain, muscle aches, fatigue) — usually after first dose and resolves within 24–48 hours
- Heartburn (dyspepsia), nausea, abdominal pain
- Esophageal disorders (esophagitis, esophageal ulcers or erosions)
- Diarrhea
- Musculoskeletal pain (bone, muscle, and/or joint pain)
- Fatigue
- Rash
Uncommon
- Dizziness
- Gastritis, gastric ulcer
- Difficulty swallowing (dysphagia)
- Vomiting, flatulence
- Back pain
- Muscle stiffness or spasms
- Pain in extremities
- Hypersensitivity reactions
- Elevated parathyroid hormone levels
Rare
- Osteonecrosis of the jaw (ONJ)
- Atypical subtrochanteric and diaphyseal femoral fractures
- Eye inflammation (uveitis, scleritis, episcleritis)
- Esophageal stricture (narrowing)
- Duodenitis (inflammation of the duodenum)
- Severe skin reactions (erythema multiforme, dermatitis bullous)
- Angioedema (swelling of face, lips, or throat)
- Bronchospasm in aspirin-sensitive patients
Very Rare
- Stevens-Johnson syndrome and toxic epidermal necrolysis
- Hypocalcemia (low blood calcium)
- Osteonecrosis of the external auditory canal
- Anaphylactic reaction/shock
Flu-Like Symptoms (Acute-Phase Reaction)
A characteristic side effect of the 150 mg monthly dose is the acute-phase reaction, which typically occurs after the first dose and diminishes with subsequent doses. Symptoms may include fever, chills, bone pain, muscle aches, joint pain, and general malaise. In the MOBILE study, flu-like symptoms were reported in approximately 4–10% of patients taking the monthly 150 mg dose, compared to 1–3% with the daily 2.5 mg dose. These symptoms usually appear within 24–72 hours of taking the tablet and resolve spontaneously within 1–2 days.
If you experience flu-like symptoms, they can usually be managed with over-the-counter analgesics such as paracetamol (acetaminophen) or ibuprofen. It is important not to confuse these transient symptoms with infection. If symptoms persist beyond 3 days or worsen, consult your doctor.
Long-Term Safety Considerations
Two rare but important adverse effects have been associated with long-term bisphosphonate use and deserve special attention:
Osteonecrosis of the jaw (ONJ) has been reported in patients receiving bisphosphonates, including ibandronic acid. The risk with oral bisphosphonates for osteoporosis is estimated at approximately 1 in 10,000 to 1 in 100,000 patient-years of treatment. Risk factors include invasive dental procedures, poor oral hygiene, cancer treatment, corticosteroid therapy, and smoking. Preventive measures include dental assessment before starting treatment, maintaining good oral hygiene, and informing your dentist about bisphosphonate use before any dental surgery.
Atypical femur fractures (fractures in the shaft of the thighbone) have been reported with long-term bisphosphonate therapy. These unusual fractures may develop with minimal or no trauma and are sometimes preceded by prodromal pain in the thigh or groin. The estimated incidence is approximately 3.2–50 cases per 100,000 patient-years with bisphosphonate use, with risk increasing with duration of therapy. If you develop new or unusual hip, groin, or thigh pain, report it to your doctor immediately. Discontinuation of bisphosphonate therapy should be considered based on individual risk-benefit assessment.
How Should You Store Bonviva?
Proper storage of medication is important to maintain its effectiveness and safety. Store your Bonviva tablets according to the following guidelines:
- Temperature: Store below 30°C (86°F). No special temperature conditions are required — normal room temperature is suitable
- Packaging: Keep the tablets in the original blister packaging to protect from moisture and light. Do not remove tablets from the blister until you are ready to take them
- Children: Keep out of the reach and sight of children. The blister packaging is child-resistant but should still be stored in a safe location
- Expiry date: Do not use Bonviva after the expiry date printed on the outer carton and blister. The expiry date refers to the last day of that month
- Disposal: Do not dispose of medicines via household waste or wastewater. Return unused or expired tablets to your pharmacy for safe disposal. This helps protect the environment
If you notice any visible changes in the appearance of the tablets, such as discoloration, crumbling, or unusual odor, do not take them. Contact your pharmacist for a replacement.
What Does Bonviva Contain?
Understanding the composition of your medication can be important, particularly if you have known allergies or intolerances to specific ingredients. Below is a detailed breakdown of what each Bonviva 150 mg film-coated tablet contains:
Active Ingredient
- Ibandronic acid 150 mg (as sodium ibandronate monohydrate 168.75 mg)
Inactive Ingredients (Excipients)
Tablet core:
- Lactose monohydrate
- Povidone (K25)
- Microcrystalline cellulose
- Crospovidone
- Stearic acid
- Colloidal anhydrous silica
Film coating:
- Hypromellose (E464)
- Titanium dioxide (E171)
- Talc
- Macrogol 6000
Bonviva contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. However, the amount of lactose per tablet is small and is unlikely to cause problems in most people with lactose intolerance.
Tablet Appearance
Bonviva 150 mg is a white to off-white, elongated (oblong) film-coated tablet, marked with “BNVA” on one side and “150” on the other side. Each monthly pack contains 1 or 3 tablets in a blister pack.
Frequently Asked Questions About Bonviva
Bonviva (ibandronic acid) is a bisphosphonate medication used to treat postmenopausal osteoporosis in women at increased risk of fracture. It works by slowing down bone loss and increasing bone mineral density, thereby reducing the risk of vertebral fractures. The 150 mg tablet is taken once a month, making it a convenient option compared to daily or weekly bisphosphonate regimens. Bonviva is not indicated for use in premenopausal women, men, or children.
Take one 150 mg tablet once a month on the same date each month, first thing in the morning on an empty stomach. Swallow the tablet whole with a full glass of plain tap water (at least 200 ml) while sitting or standing upright. Do not use mineral water, juice, coffee, tea, or milk. After taking it, remain upright (sitting or standing) for at least 60 minutes. Do not eat, drink, or take other medications during this 60-minute period. Do not chew, crush, or dissolve the tablet.
The most common side effects include musculoskeletal pain (bone, muscle, or joint pain), heartburn (dyspepsia), nausea, abdominal pain, headache, and flu-like symptoms (especially after the first dose). Flu-like symptoms typically resolve within 24–48 hours and are less frequent with subsequent doses. Serious but rare side effects include esophageal ulcers, osteonecrosis of the jaw, and atypical femur fractures. Most gastrointestinal side effects can be minimized by strictly following the dosing instructions, particularly remaining upright for 60 minutes.
The main difference is dosing frequency: Bonviva is taken once a month (150 mg) compared to once a week (70 mg) for alendronate. Studies show many patients prefer and have better adherence with monthly dosing. Both drugs are bisphosphonates that work by the same mechanism. However, Bonviva requires a longer fasting period (60 minutes vs. 30 minutes for alendronate). Both have strong evidence for reducing vertebral fracture risk, though alendronate has more robust data for hip fracture reduction. Your doctor will recommend the most suitable bisphosphonate based on your individual risk profile and preferences.
Treatment is typically reassessed after 3–5 years. Bisphosphonates are incorporated into bone and remain there for years, so a “drug holiday” may be appropriate for patients at moderate fracture risk. Patients at high fracture risk may benefit from longer treatment. Your doctor will evaluate your bone density, fracture risk factors, and treatment response to guide this decision. Regular bone density scans (DXA) and clinical assessment are recommended during treatment to monitor progress.
If your next scheduled dose is more than 7 days away, take the missed tablet the following morning. Then return to your regular monthly schedule. If your next dose is within 7 days, skip the missed dose and take your next tablet on the originally scheduled date. Never take two 150 mg tablets within the same week, as this increases the risk of side effects.
References
This article is based on international medical guidelines, peer-reviewed clinical research, and official product information from regulatory authorities. All medical claims are supported by evidence level 1A (systematic reviews and randomized controlled trials) where available.
- European Medicines Agency (EMA). Bonviva – Summary of Product Characteristics (SmPC). Last updated 2024. Available at: ema.europa.eu/en/medicines/human/EPAR/bonviva
- Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–1249. doi:10.1359/JBMR.040325 (BONE study)
- Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20(8):1315–1322. doi:10.1359/JBMR.050313
- Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65(5):654–661. doi:10.1136/ard.2005.044958
- Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005;21(12):1895–1903. doi:10.1185/030079905X74862
- National Institute for Health and Care Excellence (NICE). Bisphosphonates for treating osteoporosis. Technology appraisal guidance [TA464]. Updated 2017.
- Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update. Endocr Pract. 2020;26(Suppl 1):1–46.
- Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23. doi:10.1002/jbmr.2405
- Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23. doi:10.1002/jbmr.1998
- World Health Organization. WHO Model List of Essential Medicines – 23rd list, 2023. Geneva: WHO; 2023.
About Our Medical Editorial Team
All content on iMedic is written and reviewed by a team of licensed specialist physicians with expertise in clinical pharmacology, endocrinology, rheumatology, and internal medicine. Our editorial process follows the GRADE evidence framework and adheres to international medical guidelines from the WHO, EMA, FDA, and NICE.
All medical claims are supported by peer-reviewed research and international guidelines. We prioritize Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials).
iMedic receives no commercial funding, pharmaceutical sponsorship, or advertising revenue. Our editorial decisions are made solely based on scientific evidence and clinical relevance.
This article was last medically reviewed on . Content is updated when new evidence, guidelines, or safety information becomes available.
This page meets WCAG 2.2 Level AAA standards with screen reader optimization, keyboard navigation, high contrast support, focus indicators, and semantic HTML structure.